Pharmafile Logo

In-person, hybrid, or digital? State of Pharma meetings and events in 2024

March 18, 2024 |  

We’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put the idea of in-person meetings being superior to rest.

- PMLiVE

Whether we’re talking offices, medical congresses, or advisory board meetings, the term “hybrid” is often used to signal the ideal state. The place where everyone’s needs are being met. The best of both worlds. In the era of digital transformation, it is predicted that 2024 will be the year that finally cements hybrid meetings as the norm (1), with all-virtual meetings continuing to be a popular option. Yet, some people are holding onto the idea of in-person meetings being superior. In this article, we’re diving into the state of pharmaceutical meetings and events in 2024 and–once and for all–put this idea to rest.

Why in-person-only should be a thing of the past

I’ve written and talked about the blindspots of in-person meetings for over 16 years now, but it’s only been in the past few years that the benefits of virtual engagements have gained mainstream acceptance. There are multiple reasons why in-person-only meetings should be laid to rest, including, but not limited to, the facts that they are:

  • Expensive
  • Associated with a large environmental footprint
  • Inflexible and not accommodating to everyone’s schedules, work or personal commitments, and preferences
  • Susceptible to last-minute no-shows due to flight delays or poor driving conditions

Specifically for advisory boards and other insight-gathering initiatives, the in-person-only approach comes with additional pain points such as:

  • Valuable time wasted on didactic data presentations
  • Very limited “air time” per participant
  • Uneven share of voice, with more extroverted or senior advisors tending to take up more speaking time
  • A tendency for answers to be “knee-jerk reactions” rather than thought-through responses and for people to simply ‘agree’ with others
  • Limited ability to dive deeper into interesting or controversial ideas
  • Suboptimal diversity of advisors due to potential geographic or language barriers

Most important, though, is the fact that participants don’t want only in-person meetings. Based on our survey of hundreds of healthcare provider advisors in 2022–2023, over three-quarters stated that they prefer virtual/hybrid meetings, with the convenience and flexibility of digital meetings rated as the top benefits…

[Read the full article here]

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Modern Medical Affairs: How to Leverage Tech and Data as an MSL

Dr. Luca Dezzani, VP of US Oncology Medical Affairs at Johnson & Johnson, explores innovation in Medical Affairs, new technologies for data dissemination and medical education, how to engage with…

Partnering with Patients and Caregivers in Clinical Research

One definition of patient-centricity is “Putting the patient first in an open and sustained engagement of the patient to respectfully and compassionately achieve the best experience and outcome for that person…

Leveraging the Cloud for Patient-friendly Medical Devices

Robert Kaul, Founder, CEO & President of Cloud DX, explores connected health, remote patient monitoring, telemedicine, and more. He also shares his tips for new entrepreneurs based on his 17…

Impact of COVID-19 on the Biopsychosocial Model of Health

Dr. Tarry Ahuja, Manager of Program Development in Pharmaceutical Reviews and Senior RWE Advisor at CADTH, explores the impact of COVID-19 on the biopsychosocial model of health, key opportunities and…

Biotech Innovation in the Time of COVID-19

Chris Garabedian, CEO of Xontogeny, dives into biotech and digital health innovation, current industry gaps and obstacles, how to encourage biotech entrepreneurs, AI & machine learning, and much more!

Advancing Precision Medicine in Oncology

Jerome Madison, Host of The Precision Medicine Podcast, shares his leadership lessons and tips for building and training new sales teams in the era of precision medicine. He also dives…

Beat inflation with virtual meetings and programs

At the time of writing, the average inflation rate worldwide sits at 7.4%, the highest it’s been for decades. Here in Canada, the inflation rate is not forecasted to come back down…

Engaging KOLs & Gaining Insights in Pharma’s New Normal

Kaitlin Anstett, Senior Medical Advisor at Theratechnologies, shares her unique insights into the way Medical Affairs teams are changing the way they are engaging and interacting with their most important…

There’s No Going Back: How COVID-19 will Change Pharma Forever

Munther Baara, VP Product Strategy and Innovation at EDETEK, discusses all things clinical trials. Especially, we discuss the current gaps and the impact of COVID-19 on the way Pharma approaches…